The human pyruvate dehydrogenase complex (PDC) is a 9.5-megadalton catalytic machine that employs three catalytic components, i.e. pyruvate dehydrogenase (E1p), dihydrolipoyl transacytase (E2p), and dihydrolipoamide dehydrogenase (E3), to carry out the oxidative decarboxylation of pyruvate. The human PDC is organized around a 60-meric dodecahedral core comprising the C-terminal domains of E2p and a noncatalytic component, E3-binding protein (E3BP), which specifically tethers E3 dimers to the PDC. A central issue concerning the PDC structure is the subunit stoichiometry of the E2p/E3BP core; recent studies have suggested that the core is composed of 48 copies of E2p and 12 copies of E3BP. Here, using an in vitro reconstituted PDC, we provide densitometry, isothermal titration calorimetry, and analytical ultracentrifugation evidence that there are 40 copies of E2p and 20 copies of E3BP in the E2p/E3BP core. Reconstitution with saturating concentrations of E1p and E3 demonstrated 40 copies of E1p heterotetramers and 20 copies of E3 dimers associated with the E2p/E3BP core. To corroborate the 40:20 model of this core, the stoichiometries of E3 and E1p binding to their respective binding domains were reexamined. In these binding studies, the stoichiometries were found to be 1:1, supporting the 40:20 model of the core. The overall maximal stoichiometry of this in vitro assembled PDC for E2p:E3BP:E1p:E3 is 40:20:40:20. These findings contrast a previous report that implicated that two E3-binding domains of E3BP bind simultaneously to a single E3 dimer (Smolle, M., Prior, A. E., Brown, A. E., Cooper, A., Byron, O., and Lindsay, J. G. (2006) J. Biol. Chem. 281, 19772–19780).

The human pyruvate dehydrogenase complex (PDC) resides in mitochondria and catalyzes the oxidative decarboxylation of pyruvate to yield acetyl-CoA and reducing equivalents (NADH), serving as a link between glycolysis and the Krebs cycle (1–3). The PDC is a large (~9.5 MDa) catalytic machine comprising multiple protein components. The three catalytic components are pyruvate dehydrogenase (E1p), dihydrolipoyl transacetylase (E2p), and dihydrolipoamide dehydrogenase (E3), with E3 being a common component between different α-keto acid dehydrogenase complexes. The two regulatory enzymes in the PDC are the isofoms of pyruvate dehydrogenase kinase and pyruvate dehydrogenase phosphatase.

The PDC is organized around a structural core, which includes the C-terminal domains of E2p and a noncatalytic component that specifically binds E3, i.e. the E3-binding protein (E3BP). To this E2p/E3BP core, multiple copies of the other PDC components are tethered through noncovalent interactions. Each E2p subunit contains two consecutive N-terminal lipoic acid-bearing domains (LBDs), termed L1 and L2, followed by the E1p-binding domain (E1pBD) and the C-terminal inner-core/catalytic domain, with these independent domains connected by unstructured linkers. Similarly, each E3BP subunit consists of a single N-terminal LBD (referred to as L3), the E3-binding domain (E3BD), and the noncatalytic inner core domain. Together, the inner core domains of E2p and E3BP assemble to form the dodecahedral 60-meric E2p/E3BP core. The role of the E1pBD and E3BD domains is to tether E1p and E3, respectively, to the periphery of the E2p/E3BP core. It is presumed that the LBDs (L1, L2, and L3) shuttle between the active sites of the three catalytic components of the PDC during the oxidative decarboxylation cycle (4). The eukaryotic PDC is unique among α-keto acid dehydrogenase complexes in its requirement for E3BP; prokaryotic PDCs employ the single subunit-binding domain to secure either E1p or E3 to the complex (5).

Using a “divide-and-conquer” approach, a wealth of structural information on the PDC has been accumulated recently. High-resolution crystal structures are available for the human E1p (6–8) and E3 components (9). A model for the human E2p has been constructed based on an 8.8-Å electron density map available from cryo-electron microscopy (10). Additionally, solution and crystal structures of the L1 and L2 domains of E2p have been determined (11–13), and the high-resolution crystal

TEV, tobacco-etched virus; IF, interference; ABS, absorbance; FPLC, fast protein liquid chromatography.
structures of the E3BD (14, 15), pyruvate dehydrogenase kinase isoforms 1–4 (12, 16–18), and pyruvate dehydrogenase phosphatase isoform 1 (19) are known. Therefore, atomic models are available for almost all components and domains of the mammalian PDC.

With the successes of the above structural approach, attention has turned to the overall structure of the PDC. There are two outstanding questions as follows. What are the subunit and overall catalytic component stoichiometries? What are the positions and orientations of the components in this large catalytic machine? Yu et al. (10) recently determined the cryo-EM structure of a PDC core comprising only human E2p subunits. Like yeast E2p, human E2p adopts a dodecahedral structure composed of 60 E2p proteins; each face of the dodecahedron has a large gap. Although this structure is highly informative, the composition of this core deviates substantially from that of the native PDC, because no E3BP subunits are present in the core structure. Based on the similar structure of the dodecahedral yeast PDC, a hypothesis was formed that, in human PDC, 12 copies of E3BP bind in the 12 gaps, which is termed the “60/12” model (20). Biophysical studies on complexes of E2p and E3BP later negated the 60/12 model; Hiromasa et al. (21) therefore proposed an alternative, the “48/12” model, in which the dodecahedral core includes 48 E2p subunits and 12 E3BP proteins. A further source of conjecture is how many E1p and E3 components bind to the periphery of the PDC. If one binding domain binds to one peripheral catalytic component, a maximally occupied 60/12 PDC would harbor 60 E1p heterotetramers and 12 E3 dimers (or 48 E1ps and 12 E3s in the 48/12 model). The notion of such 1:1 binding is supported by the preponderance of available biophysical evidence. Specifically, two crystal structures, site-directed mutagenesis, and calorimetric measurements describe a 1:1 association between E3BD and E3 (14, 15). Additionally, although no structures are available for the human E1p-E1pBD complex, a crystal structure of the homologs of these proteins from Bacillus stearothermophilus also demonstrates a 1:1 interaction between the E1pBD of E2p and the E1p heterotetramer (22). In addition, ITC experiments performed on the bacterial E1p and the cognate subunit-binding domain indicate a 1:1 association (23). At variance with the above observations, a different subunit stoichiometry has been proposed by Smolle et al. (24, 25). Their evidence suggests that two binding domains bind for every peripheral component; such an arrangement potentially yields a PDC with half as many peripheral components bound.

This study was undertaken to ascertain the subunit and component stoichiometries of the human PDC, particularly with regard to interactions between the E3BD and the E3 dimer. We show that quantification of bands on an SDS-polyacrylamide gel of a PDC reconstituted at saturating E1p and E3 concentrations supports neither the 60/12 nor the 48/12 model. Instead, a “40/20” model is proposed, and subsequent ITC and analytical ultracentrifugation (AUC) data corroborate this new model. In addition, results from electrophoretic mobility shift assays, ITC, and AUC presented here uniformly show a 1:1 interaction between E3BD and the E3 dimer as well as between E1pBD and the E1p heterotetramer. The implications of this 1:1 binding stoichiometry for the macromolecular assembly of the PDC are discussed.

**EXPERIMENTAL PROCEDURES**

**Protein Expression and Purification**—Recombinant human E3 (9, 14) and E1p (7) were expressed and purified as described previously. The recombinant fusion protein LBDb-E3BD was constructed, expressed, and purified as described before. Descriptions and schematic representations of the LBDb-E1pBD, LBDb-E3BD, L3-E3BD, and XDD1 constructs in the pET28b expression vector can be found under “Results and Discussion” (see Fig. 2). The expression plasmids for human E1p and the full-length human E2p/E3BP core were generous gifts from Dr. Kirill Popov, University of Alabama Medical Center, Birmingham, AL (26). For use as a protein standard, the E2p expression construct was generated by the deletion of a SalI fragment containing the mature E3BP coding sequence from the E2p/E3BP plasmid. The E3BP construct was prepared by amplifying the cloning sequence for mature E3BP from the E2p/E3BP plasmid; the amplified DNA fragment was also cloned into the pET28b expression vector.

All E3BD-containing proteins were expressed in *Escherichia coli* BL21 DE3 pLys S cells (Novagen, San Diego, CA). Lipoic acid was added to the growth media to a final concentration of 0.2 mM before induction with 0.5 mM isopropyl-1-thio-β-D-galactopyranoside. After overnight growth at 30 °C, harvested cells were suspended in the lysis buffer (100 mM potassium phosphate, pH 8.0, 500 mM NaCl, 1% (v/v) Triton X-100, 0.5% (v/v) Tween 20, 10% (v/v) glycerol, 1 mM benzamidine, 1 mM phenylmethylsulfonyl fluoride, and 20 mM β-mercaptoethanol) and disrupted by the addition of lysozyme and sonication. Cleared cell extract was treated with nickel-nitritotriacetic acid resin (Qiagen, Valencia, CA), and the eluted protein was further purified on a Superdex 200 26/60 column (GE Healthcare) that had been equilibrated with 50 mM potassium phosphate, pH 7.5, 150 mM KCl, 5% (v/v) glycerol, and 20 mM β-mercaptoethanol. The E3BD protein (E3BP residues 121–175) was prepared by incubating LBDb-E3BD protein with the TEV protease (100:1 (w/w)) for 24 h at 4 °C, followed by nickel-nitritotriacetic acid extraction and purification on a Sephacryl S-100 column equilibrated in the same buffer. The recombinant E2p/E3BP core and E2p core proteins were expressed and purified according to the method described by Hiromasa et al. (21); a key modification was that the E2p/E3BP core and E2p core proteins in the absence of detergent were purified from the pellet of the first 8% (w/v) polyethylene glycol 8000 precipitation. The individually expressed E3BP protein was purified from the pellet of the second 8% polyethylene glycol 8000 precipitation, followed by purification on gel filtration and FPLC Resource Q column.

**Protein Concentration Determination**—At least two different measurements were used to determine the concentrations of the individual proteins. For E3, the absorbance of the flavin chromophore at 450 nm (ε<sub>450 nm</sub> = 10,325 M<sup>-1</sup> cm<sup>-1</sup>) was monitored. Alternatively, E3 was precipitated using trichloroacetic acid, washed with trichloroacetic acid, and then dis-
Solved in guanidinium hydrochloride to remove the bound FAD; the absorbance of E3 at 278 nm ($\varepsilon_{278\text{ nm}} = 23,971 \text{ M}^{-1} \text{ cm}^{-1}$) was used to determine the concentration of E3. The concentrations of LBD-B-E1pBD, LBD-B-E3BD, L3-E3BD, and XDD1 were determined by using the calculated extinction coefficients ($\varepsilon_{280\text{ nm}}$) of 14,000, 14,435, 11,000, and 11,000 M$^{-1}$ cm$^{-1}$, respectively, and colorimetrically by the advanced protein determination assay (Cytoskeleton, Inc., Denver, CO). Because the E3BD sequence does not contain any UV-absorbing aromatic amino acid residues, a colorimetric assay was used to determine its protein concentration.

The subunit-binding domain from E2b of the BCKDC was subjected to SDS-PAGE and stained with Coomassie blue. The molar extinction coefficients described above were used. Results from the experiment were obtained with individual protein standards. The molar extinction coefficients alone and by comparing with the standard curves of the subunit obtained by direct titration. The raw data from the interferometer can be expressed in terms of the “number of fringes displaced,” termed $\Delta I$. This quantity is related concentration of the protein by an equation that is similar to the familiar Beer-Lambert law as shown in Equation 1,

$$\Delta I \equiv C M l c$$

where $c$ is concentration (expressed in mol/liter); $M$ is the molar ratio ($n$), and the enthalpy change ($\Delta H$). $K_d$ was converted to the dissociation constant ($K_d$) using the relationship $K_d = 1/K_p$. Curve fitting and the derivation of thermodynamic parameters were carried out using the nonlinear parameter optimization protocols implemented in the ORIGIN version 7.0 software package provided by MicroCal. The concentrations of the proteins were determined as described above.

Analytical Ultracentrifugation—All analytical ultracentrifugation sedimentation velocity (SV) experiments were carried out in a model XL-1 (Beckman-Coulter, Fullerton, CA) centrifuge. Experiments with LBD-B-E3BD were carried out in a buffer composed of 50 mM potassium phosphate, pH 7.5, 12 mM KCl. These studies were performed at 20 °C in an An60-Ti rotor (Beckman-Coulter) using a rotor speed of 50,000 rpm. The buffer for the experiments with L3-E3BD and XDD1 included 20 mM Tris-HCl, pH 7.5. They were performed using a rotor speed of 45,000 rpm at 4 °C in an An50-Ti rotor (Beckman-Coulter). AUC studies featuring reconstituted PDC with either E1p or E3 were done at 20 °C, with rotor speeds of 15,000 or 20,000 rpm, respectively, in the An50Ti rotor. All AUC experiments were carried out in dual-sector charcoal-filled Epon centerpieces fitted with sapphire windows; all sample volumes were ~390 μl. Both the on-board laser interferometer and UV-visible spectrophotometer were used to monitor the sedimentation of the proteins. The partial specific volumes of the proteins, the buffer viscosity, and the buffer density were estimated using the freeware program SEDNTERP (27). The initial qualities of the experiments were analyzed by performing simple c(s) analyses, in which the raw data are directly modeled as a continuous distribution of noninteracting, ideally sedimenting species. The freeware program SEDFIT (28, 29) was used for such analyses.

Although the concentrations of the proteins included in all SV experiments were estimated using UV spectrophotometry, the laser interferometer in the XL-1 centrifuge was used as an independent, unbiased means for determining protein concentration. The raw data from the interferometer can be expressed in the terms of “number of fringes displaced,” termed $\Delta I$. This quantity is related concentration of the protein by an equation that is similar to the familiar Beer-Lambert law as shown in Equation 1,
molar mass of the species; \( l \) is the optical path length (1.2 cm in this case), and \( C_f \) is a constant with a value of 2.75 fringes/liter cm\(^{-1} \). The term \( C_f M_t \) assumes the place of the conventional extinction coefficient in this Beer-Lambert-like formulation; this term should be applicable for all proteins that do not have significant post-translational modifications, such as glycosylation. This term throughout this paper is referred to as “\( \epsilon_{IF} \)”, making Equation 1 take the form shown in Equation 2,

\[
\Delta J \approx \epsilon_{IF} / C_t \tag{2}
\]

In practice, \( \epsilon_{IF} \) was calculated using Equation 3,

\[
\epsilon_{IF} = 2.75M_t \tag{3}
\]

where \( M_t \) is the predicted molar mass of the protein based on its amino acid sequence. The mass of the FAD cofactor was not considered in calculating the \( \epsilon_{IF} \) of E3. In an SV experiment with only one protein, \( \Delta J \) is observed; \( J \) is known, and \( \epsilon_{IF} \) is easily calculated using Equation 3. Therefore, the only unknown in Equation 2 is \( c \), allowing its calculation from the experimentally observed \( \Delta J \).

In the SV experiments presented in this work, there are usually two boundaries: a leading boundary, representing the cosedimenting complexes of the larger and smaller proteins, and a lagging boundary that represents excess free smaller protein. For most of these experiments, three methods were used to determine the concentrations of the smaller protein that cosedimented with the larger. In the first, called the “lagging” method, the concentration of lagging material was quantified using Equations 2 and 3. Because a known concentration of lagging protein was input, the lagging concentration was subtracted from the input concentration, and this value was taken as the amount of lagging protein in the complex. For the second method, \( \Delta J \) for the leading boundary was determined. From this value, the input \( \Delta J \) of the larger protein was subtracted. This latter value was taken as the signal because of the cosedimenting smaller protein. For experiments performed at 4 °C, the sample meniscus for the IF data refined to unrealistic values, likely indicating that some convection was present in the sample. In these cases, the meniscus was fixed at a position that corresponded to an optical artifact in the data that has reliably represented the meniscus in past experiments.

**Results and Discussion**

**Subunit and Molar Stoichiometries of the Human PDC Reconstituted in Vitro**—The organization of the human PDC was investigated by in vitro assembly using individually purified recombinant E1p, E3, and the E2p/E3BP core proteins. The 60-meric E2p/E3BP core was incubated with molar excesses of E3 dimers and/or E1p heterotetramers. The assembly mixture was passed through an FPLC Superdex 200 column to remove excess unbound E3 and/or E1p components. The purified reconstituted PDC was subjected to SDS-PAGE and stained with Coomassie Brilliant Blue (Fig. 1A). Subunit stoichiometries of the assembled PDC were estimated by comparing the staining intensity of each band and by estimating the amount of each subunit from the standard curve obtained with individual protein standards. The subunit:component ratio of E2p:E3BP: E1p heterotetramer:E3 dimer is 43 ± 2.4:20:36.9 ± 5.3:18.6 ± 1.1 by direct comparison of staining intensity and 48.7 ± 2.2:20:38.2 ± 4.3:16.1 ± 0.8 by comparing to the standard curves, with nine experiments for both methods. The component ratios are indexed to the E3BP subunit. These results support a stoichiometry of E2p:E3BP:E1p:E3 = 40:20:40:20.

The present subunit ratio of E2p:E3BP = 40:20, estimated by staining intensity or by comparison with individual standard curves, is different from that of 48:12 reported previously by Roche and co-workers (21). Our E2p:E3BP subunit ratio also disagrees with the 6–12 copies of E3BP in the PDC estimated previously (20, 33). The 40:20 subunit ratio that we propose would be consistent with a dodecahedral arrangement of 20

**Stoichiometries of a Reconstituted Human PDC**
heterotrimers, with each E2p/E3BP heterotrimer harboring two E2p subunits and one E3BP subunit. In contrast, based on the ratio of E2p:E3BP = 48:12 reported previously, a fraction of trimers in the E2p/E3BP core would be devoid of the E3BP subunit. The molecular ratio of E1p:E3:E2p/E3BP = 40:20:1 obtained by examination of the present in vitro assembly also differs from that of the 30:6:1 reported previously for the native bovine heart PDC (20, 34). However, the present ratio of E1p: E3:E2p/E3BP = 40:20:1 was achieved through in vitro assembly at saturating E1p and E3 concentrations. The results suggest that the E1p- and E3-binding sites in the E2p/E3BP core in the native PDC complex are not fully occupied by these two catalytic components. This raises the possibility that the copy numbers of E1p and E3 components may play a role in regulating
PDC activity, as proposed for the E1b component of mammalian BCKDC (35).

Sedimentation velocity (SV) AUC experiments were used to examine the hydrodynamic behavior of the E2p/E3BP core in the absence and presence of E3. The $s_{20,w}$ of core alone is 30.4 ± 0.2 S (Fig. 1B). In the presence of saturating concentrations of E3, the $s_{20,w}$ increases to 43.3 ± 0.4 S, indicating a substantial increase in size (Fig. 1B). For these analyses, three different means of calculating the concentration of cosedimenting E3 were employed (see “Experimental Procedures”). If the concentration of the core complex is calculated using the putative heterotrimer of two E2ps and one E3BP, the molar ratio of heterotrimer to E3 dimer was found to be close to 1:1. Indeed, if all three methods are combined to yield a single average, the molar ratio of heterotrimer to E3 is 1.0 ± 0.2. This ratio translates into an average of 20 ± 4 E3s bound per core complex. The concentration of the core complex can also be calculated on the basis of the 48/12 model; in this case, the core can be conceptualized as comprising 12 heterotetramers of four E2ps and one E3BP. When calculated based on the 48/12 model, the molar ratio of E3 to heterotrimer is 1.7 ± 0.4, corresponding to 21 ± 5 E3 dimers cosedimenting with the complex.

The hydrodynamic properties of the interactions between E1p and the E2p/E3BP core were also studied. In a preliminary experiment, the core was incubated in the presence of a molar excess of E1p heterotetramers. When subjected to SV, the resultant complex had a sedimentation coefficient of about 70 S (Fig. 1B). Using the “Leading” method described under “Experimental Procedures,” the E1p co-sedimenting with the E2p/E3BP core was quantified. Assuming a 40/20 core, the result is nearly identical to the 48/12 model; in this case, the core can be conceptualized as comprising 12 heterotetramers of four E2ps and one E3BP. When calculated based on the 48/12 model, the molar ratio of heterotrimer to E3 dimer is 1.7 ± 0.4, corresponding to 21 ± 5 E3 dimers cosedimenting with the complex.

ITC was also used to characterize the interaction between E3 and the E2p/E3BP core. When the E3 dimer was titrated into the reaction cell containing the E2p/E3BP core, a binding isotherm is obtained (Fig. 1C) that can be easily fit to obtain an association constant and a binding stoichiometry ($n$). First, the core concentration was calculated on the basis of the 40/20 complex; the $K_d$ of the E3:E2p-E3BP interaction was 102 ± 7.5 nM, with an $n$ value of 18.8 ± 0.94. When calculating the core concentration based on the 48/12 model, the $K_d$ and $n$ values are 102 nM and 17, respectively.

The binding of E1p to the E2p/E3BP core was also deciphered by ITC (supplemental Fig. S1A). The titration of E1p into the E2p/E3BP core produced an isotherm that could be fit with a $K_d$ of 218 ± 8.6 nM in three independent experiments. Significantly, the $n$ value is 40.5 ± 3.6 based on the E2/E3 stoichiometry of 40:20. The data indicate that the E2p/E3BP core maximally binds 40 copies of E1p heterotetramers at saturating E1p concentrations. The $n$ value is 38 ± 3.4, if the protein concentration is based on the 48/12 E2p/E3BP model, again indicating unused binding potential if the 48/12 model is correct.

**E1pBD- and E3BD-containing Constructs Studied** — The data presented above, when combined with the assumption that one binding domain (either E1pBD or E3BD) binds to one peripheral catalytic component (E1p heterotetramer or E3 dimer, respectively), provide strong support for the 40/20 model of the E2p/E3BP core postulated herein. Although the preponderance of evidence supports the 1:1 binding stoichiometry (5, 14, 15), this supposition has been challenged in the literature recently with respect to the E3BP-E3 interactions (24, 25). To provide additional empirical grounds for the 40/20 model, studies on the E1p- and E3-binding domains of E2p and E3BP, respectively, were carried out and are described below.

To facilitate its expression, the E1pBD domain (mature E2p residues 260–315) was N-terminally linked to the LBDb of the E2b component of the BCKDC. The resulting LBDb-E1pBD construct harbored a TEV protease-recognition site immediately proximal to the E1pBD sequence and a C-terminal His$_6$ tag (Fig. 2A). As for E3 binding studies, the ideal means of determining how many E3 dimers may bind to an E3BP monomer would be to overexpress and purify E3BP. However, the E3BP protein, when overexpressed in *E. coli*, is not suitable for biophysical characterization, because it forms unstable putative dimers that aggregate at higher concentrations (data not...
shown). Therefore, soluble versions of E3BP were constructed; these proteins harbor LBDs and E3BDs but not the C-terminal domain of E3BP (Fig. 2). As also shown in Fig. 2A, the LBDb-E3BD construct includes residues 121–175 (the mature sequence numbering) of human E3BP (26), which included the full-length E3BD (residues 130–170) (Fig. 2B) based on the E3BD structure (14). The L3-E3BD construct included an N-terminal methionine, residues 1–175 of mature E3BP. The XDD1 protein (mature sequence residues 1–163) was used to mimic the XDD construct (nonprocessed sequence residues 59–216 or mature sequence residues 6–163) that had been studied by Smolle et al. (25). The XDD1 construct contains the same C-terminal truncation of seven amino acid residues in the E3BD as reported for the XDD vector (Fig. 2A). However, unlike the XDD construct, XDD1 does not contain the N-terminal deletion of five amino acids in the L3 domain; the latter domain does not interact with the E3 dimer. It is important to note that both XDD1 and XDD feature only half of the H2 helix of the E3BD structure (14), as a result of the C-terminal truncation (Fig. 2B).

Analytical Ultracentrifugation Studies of E3 Binding to E3BD-containing Proteins

SV was used to study the behavior of all three E3BD-containing proteins in the presence of E3 (Fig. 3). For E3 alone, there is a dominant peak at 5.64 ± 0.03 S according to the $c(s)$ distribution (Fig. 3). When combined with the refined frictional ratio, these $c(s)$ values can be used to estimate the mass of the sedimenting species using Svedberg’s equation; the mass values thus obtained in these experiments (115 ± 4 kDa) conform to the expectation that E3 is a dimer (calculated dimeric mass: 115 kDa).

### Table 1

| Input molar ratio (LBDb-E3BD/E3) | Molar ratio of interacting LBDb-E3BD/E3 |
|---------------------------------|----------------------------------------|
|                                | MWL          | Lagging $^a$ | Leading $^b$ |
| 6.1                            | 1.1          | 0.7          | 1.3          |
| Overall average                |              |              | 1.0 ± 0.3    |

$^a$ This value was calculated using the concentrations obtained by integrating the peak at ~6 S of the $c(s)$ distributions. MWL indicates multiwavelength.

$^b$ This value was measured by subtracting the observed concentration of LBDb-E3BD from the input concentration.

$^c$ This value was measured by subtracting the input signal of E3 from the signal observed at ~6 S and then calculating the concentration of cosedimenting LBDb-E3BD.

### Table 2

| Input molar ratio (L3-E3BD/E3) | Molar ratio of interacting L3-E3BD/E3 |
|---------------------------------|----------------------------------------|
|                                | MWL          | Lagging | Leading |
| 1.3                            | 1.1          | 0.9     | 0.8     |
| 2.6                            | 0.9          | 1.3     | 1.0     |
| 4.2                            | 0.6          | 1.5     | 0.9     |
| 6.7                            | 0.8          | 1.0     | 1.2     |
| 13                             | 1.1          | 1.2     | 1.0     |
| Averages                       | 0.9 ± 0.2    | 1.2 ± 0.2 | 1.0 ± 0.1 |
| Overall average                | 1.0 ± 0.2    |          |          |

$^a$ Calculation methods are as outlined in Table 1. MWL indicates multiwavelength.

### Table 3

| Input molar ratio (XDD1/E3) | Molar ratio of interacting XDD1/E3 |
|-----------------------------|------------------------------------|
|                            | MWL          | Lagging | Leading |
| 1.6                         | 1.3          | 0.6     | 1.1     |
| 3.4                         | 1.1          | 1.1     | 1.3     |
| 5.0                         | 1.1          | 0.6     | 1.6     |
| 8.3                         | 1.2          | 1.3     | 1.5     |
| 17                          | 1.1          | 1.4     | 1.4     |
| Averages                    | 1.1 ± 0.1    | 1.0 ± 0.4 | 1.4 ± 0.2 |
| Overall Average             | 1.2 ± 0.3    |          |          |

$^a$ Calculation methods are as outlined in Table 1. MWL indicates multiwavelength.
Stoichiometries of a Reconstituted Human PDC

mass = 105 kDa). Often, a second, minor peak appears at ~8 S, indicating a high molecular weight contaminant or oligomerization of E3. Using the program HYDROPRO (36), it is possible to use bead modeling to predict the hydrodynamic properties of a protein from the coordinates of its crystal structure. Such modeling using the crystal structure of E3 (9) resulted in a predicted sedimentation coefficient of 5.678 S for the E3 dimer, which agrees with the experimental observation. The observed \( s_{20,w} \) values for LBDb-E3BD, L3-E3BD, or XDD1 were 1.7, 1.6 ± 0.1, and 1.4 ± 0.1 S, respectively. The refined frictional ratios \( f/f_0 \) of these three proteins, 1.5, 1.7 ± 0.1, and 1.7 ± 0.1, respectively, indicate that the proteins adopt an elongated conformation. The masses for all three proteins, when estimated as delineated above (19.2, 23.0 ± 2.2, and 19.6 ± 1.4 kDa, respectively), are consistent with the calculated monomeric molecular masses of the proteins (19.4, 20.0, and 18.7 kDa, respectively). When LBDb-E3BD (17.1 μM) is included in solution with E3 (31. μM), there are two peaks present in a \( c(s) \) distribution: one at 1.75 S, representing free LBDb-E3BD; and one at 5.97 S, presumably representing the complex between the two proteins (Fig. 3A). The sedimentation of L3-E3BD in the presence of E3 is similar, with peaks at 1.62 ± 0.07 S and at 5.81 ± 0.03 S (Fig. 3B). Finally, XDD1 and E3 together in solution exhibited two peaks at 1.44 ± 0.08 S and 5.81 ± 0.02 S (Fig. 3C). As expected, the complex of E3 and an E3BD-containing protein therefore sediments faster than either protein alone \( (p < 0.0001 \text{ for both the L3-E3BD:E3 complex and the XDD1-E3 complex).} \)

As with the PDC core complexes with E3, the SV experiments with the E3BD-containing proteins were evaluated to determine the stoichiometries of the cosedimenting complexes. The results are shown in Tables 1–3; samplings of the multisignal SV results are shown in Figs. 4 and 5 and supplemental Fig. S2. All three methods of examining the concentrations of cosedimenting E3 and E3BD-containing protein indicate that there is a 1:1 complex between the E3 dimer and any E3BD-containing proteins. Even under conditions that would most favor the binding of a second E3BD-binding protein, i.e. a large molar excess of L3-E3BD or XDD1, there is no indication that a second protein binds to the E3 dimer.

**ITC Measurements of E3 and E1p Binding to E3BD- and E1pBD-containing Proteins**—The thermodynamic characteristics of E3 binding to E3BD-containing proteins were studied using ITC. As reported previously (14), the association of E3 with nonfused E3BD alone is exothermic and has a high association constant \( (i.e. \text{ a low } K_{\text{a}}, \text{ Fig. 6A). Indeed, the sudden saturation of E3 by E3BD precludes accurate determination of } K_{\text{a}} \text{ but the stoichiometry of the interaction should be accurate}} \)

---

\(^4\) No error estimates were given for the values associated with LBDb-E3BD because only one experiment was performed with this protein.
This experiment, which was performed in quadruplicate, yielded an average $n$ value of 0.9 ± 0.1, i.e. one E3BD binds per E3 dimer. A similar result was obtained when titrating LBDb-E3BD into E3 (Fig. 6B); the $n$ value was 1.0 ± 0.1. L3-E3BD and XDD1 have lower affinities for E3, and therefore the $K_d$ values could be reliably calculated from the integrated heat changes upon injection. They are 37 ± 5 and 200 ± 30 nM, respectively (Fig. 6, C and D). Nevertheless, the $n$ values in both the L3-E3BD and XDD1 experiments were nearly 1.0 ± 0.05 and 0.95 ± 0.06, respectively. No evidence for a second binding event could be detected in any of the ITC experiments. Significantly, the $K_d$ of E3 binding to XDD1 is 6-fold higher than that for E3 binding to the equivalent XDD construct reported previously (25). In addition, the latter study showed that two XDD molecules apparently bind one E3 dimer. The differences in buffer systems used and in the temperature of the experiments likely account for the divergent $K_d$ values, but it is unlikely that the titration conditions explain the differing binding stoichiometries.

In parallel ITC studies, an E1pBD-containing construct LBDb-E1pBD was titrated into the E1p in the reaction cell (supplemental Fig. S1B). The binding isotherm shows a $K_d$ of 103 ± 6.2 nM and an $n$ value of 0.96 ± 0.09 in three independent experiments. The $n$ value indicates a 1:1 stoichiometry for the binding of LBDb-E1pBD to the E1p heterotetramer. Taken together, the ITC results establish a 1:1 stoichiometry for E1p and E3 interactions with their respective binding domains.

Native Gel Analysis of E3 Binding to E3BD-containing Proteins—Native PAGE was used to further establish the binding stoichiometries between the E3 dimer and E3BD-containing proteins. A fixed concentration of the E3 dimer was titrated with increasing concentrations of E3BD-containing proteins, and the reaction mixtures were analyzed by native PAGE (Fig. 7). When substoichiometric quantities of LBDb-E3BD were added to E3, two bands are observed (Fig. 7A); the lower bands represent the LBDb-E3BD:E3 complex, and the upper bands represent free E3 dimers. The E3BD-containing proteins studied here (LBDb-E3BD, L3-E3BD, and XDD1) are more negatively charged (calculated pI 5.32, 6.0, and 5.58, respectively) than the E3 dimer (calculated pI = 6.66), but they add relatively little mass to the complex. Therefore, the binding of these proteins to E3 is expected to result in an increased mobility for the complex in native PAGE. In the % polyacrylamide gels, LBDb-E3BD migrated with the dye front off the gel and is therefore not visible. When the two proteins are present at a 1:1 ratio, the upper band completely disappears, indicating that all of the E3 is present as a complex with LBDb-E3BD. No enhancement or migration change of the lower band is evident upon further additions of LBDb-E3BD (data not shown). For L3-E3BD comprising the first two domains of E3BP of PDC, the same pattern

FIGURE 5. $c_i(s)$ distributions obtained from multisignal sedimentation velocity experiments with XDD1 and E3. The scheme for color, symbols, and for shown data is the same as in Fig. 6. A, data and fit to the data for the IF optical system. B, data and fit to the data for the ABS (276 nm) optical data. C, $c_i(s)$ distributions. For this distribution, the areas beneath the peaks at $-6.5$ are 3.2 μM (red, E3) and 3.4 μM (green, XDD1).

5 Nanomolar and subnanomolar $K_d$ values may be accurately determined using a “displacement ITC” experiment (43). Such an experiment has been performed for the LBDb-E3BD:E3 interaction, and the affinity was found to be 780 pM (14).
is observed (Fig. 7B). When one molecule of L3-E3BD is present per E3 dimer, only the lower band (the L3-E3BD-E3 complex) is present. When greater than 1:1 stoichiometric quantities of L3-E3BD are added relative to the E3 dimer, the excess L3-E3BD starts to appear as the faster moving band below the complex. The constant faint band below the L3-E3BD is a minor contaminant from the E3 sample.

**Anomalous Native Gel Profiles with the C-terminally Truncated XDD1 Construct**—The binding of XDD1, which mimics the XDD construct reported by Smolle et al. (25), to E3 was also studied using native PAGE. Fig. 7C shows that with increasing XDD1:E3 dimer ratios (from the left to the right side of the gel), there is a subtle increase of the faster moving band than E3, which presumably corresponds to the XDD1-E3 complex band. However, free XDD1 is present even at XDD1:E3 ratios below 1:1. At the 1:1 stoichiometry of XDD1:E3 dimer, a significant amount of the free XDD1 band is still present. The minor band below the XDD1 band is a contaminant of the XDD1 protein. The similar pattern persists at the XDD1:E3 dimer ratios of 1.5:1 and 2:1, accompanied by the increasing intensity of the free XDD1 band. We interpret the data to indicate that, unlike its full-length counterpart (L3-E3BD), the C-terminal truncated XDD1 construct binds the E3 dimer weakly (see ITC-binding results in Fig. 6D) under the conditions of the electrophoretic experiment. Also, the fact that the upper gel band adopts a presumably intermediate position between the free E3 and XDD1:E3 complex band suggests that this system behaves like those described by Gilbert and Jenkins (38, 39); the $k_{off}$ of the interaction is likely to be instantaneous on the time scale of the electrophoretic experiment. Accordingly, the binding stoichiometry between XDD1 and the E3 dimer cannot be determined by the native PAGE method.

Although the 1:1 stoichiometry of E3BD-containing proteins associating with E3 dimers presented above lends credence to previous work (5, 14, 40), it is in stark contrast to that reported by Smolle et al. (25). Their studies suggested that two copies of their E3BD-containing XDD construct bind to one E3 dimer near the 2-fold axis of the larger protein. This arrangement seems unlikely, given that two independently obtained crystal structures (14, 15) of the E3-E3BD complex showed that two copies of E3BD could not simultaneously bind to the E3 dimer. This situation arises because the two binding sites for E3BD on E3 overlap, crossing the local 2-fold axis of the dimeric protein; therefore, the binding of one E3BD sterically precludes the binding of a second (Fig. 8A). Solution binding evidence in conjunction with site-directed mutagenesis indicated that the
crystallographically observed E3-E3BD interface was correct (14). Smolle et al. (25) further suggest that E2p can be cross-linked in the periphery of the PDC by virtue of two E3BDs interacting with a single E3. Our data offer no evidence for such cross-links. It is important to note that active site couplings through transient cross-links between LBDs do exist in the PDC (41, 42). For example, an LBD with a reduced lipoic moiety from E2p could interact with the active site of E3. During the time that this LBD resides on E3, E2 and E3BP are noncovalently cross-linked via their mutual interaction (at different sites) with E3 (Fig. 8B). Once E3 has catalyzed the oxidation of the lipoic acid moiety at its active site, it is likely that the LBD will be released, breaking the cross-link. The extensive interaction network between LBDs has been suggested as a mechanism for catalytic rate enhancement in the E. coli PDC (41, 41, 42).

The results of hydrodynamic and E3-binding properties that we obtained here with the XDD1 construct differ significantly from those reported for the XDD by Smolle et al. (25). Both constructs contain the C-terminal truncation of seven amino acids in the helix 2 of E3BD (Fig. 2A). Yet, XDD1 has an $s_{20,w}$ of 2.0 S, whereas that of XDD1 is 1.4 S (Fig. 3C); the former suggests a compact, globular structure, whereas the latter indicates an elongated structure that would be expected of a protein that consists of two domains tethered by a flexible peptide linker. Additionally, their putative (XDD)$_2$-E3 complex has the same sedimentation coefficient as E3 (indicating a significantly elongated complex), whereas the XDD1-E3 complex has a greater sedimentation coefficient than E3 alone (Fig. 3C). Furthermore, in their titration experiments monitored by native PAGE, no 1:1 intermediate complex was observed, implying that there is significant cooperativity in the XDD-E3 interaction; however, no cooperativity was mentioned in the analysis of their ITC data (25). XDD1, conversely, bound only very poorly under the conditions of the electrophoretic assay, and the weaker binding is supported by the ITC data (Fig. 6D). The causes of the significant differences between the two proteins are not immediately evident, because the exact vector construction and amino acid composition of XDD were not described (25). Regardless, claims of the superstoichiometric binding of E3BD to E3 are not supported by our data.

**Implications for the Overall Architecture of the PDC**—The model studies presented above clearly demonstrate that a single E3BD-containing protein interacts with a single E3 dimer. We also show that ~20 E3 dimers associate with the E2p-E3BP core complex. The model data therefore firmly establish that there must be 20 copies of E3BP in the core. Moreover, we have demonstrated that 40 E1p heterotetramers bind to the core complex, and that the binding stoichiometry of E1pBD to E1p is 1:1. These facts allow the conclusion that there are 40 copies of E2p in the core. Therefore, the evidence points to a 40/20 model for the reconstituted E2p/E3BP core. A hypothetical arrangement for such a core is shown in Fig. 8C. All 20 vertices of the dodecahedral core include a heterotrimer of two E2ps and one E3BP. The protein-protein contacts at the midpoints between vertices (a local 2-fold) are made only by subunits. The 40/20 model presented here is a possible configuration of the PDC core that has some appealing features. Unlike the 48/12 model, the 40/20 model features an identical building block at all 20 vertices of the dodecahedron, a heterotrimer of two E2p subunits and one E3BP subunit. The 40/20 arrangement also allows for more E3 subunits to bind, which could result in the more efficient functioning of the PDC.

The results described in this study are incompatible with an earlier model of the core posited by Hiromasa et al. (21). Using methods similar to those employed here, these authors concluded that the PDC core includes 48 copies of E2p and 12 of E3BP. Their conclusions were largely based on titrating either E1p or E3 into solutions of E2p/E3BP core and quantifying the concentration of the smaller protein that cosediments with the core. They found that ~48 copies of E1p and 12 copies of E3 bound to a reconstituted core. Using the supposition of 1:1 ratios of the binding domains to the peripheral subunits, it was concluded that the stoichiometry of the E2p/E3BP core is 48:12. However, their estimation of E3 subunits may have been low. One means of quantification of E3 was performed by extrapolation of the linear part of a
graph of E3:core ratio versus apparent sedimentation coefficient (and radius of gyration using small angle x-ray scattering). However, the maximal values obtained by these methods were not obtained until the E3:core ratio was greater than 20 (21). Another means used by Hiromasa et al. (21) to quantify the number of E3 subunits was similar to the leading methodology employed in this study (see “Experimental Procedures”). The concentration of E3 used in the previously reported experiment was such that only 20 E3 dimers were present for every core, a situation under which the core would not be saturated in our model.

Acknowledgment—We are indebted to Masato Kato for the discussion and help in producing the graphics of the E2p and E3BP subunit arrangement in the 40/20 model.

REFERENCES

1. Reed, L. J. (2001) J. Biol. Chem. 276, 38329–38336
2. Reed, L. J., Damuni, Z., and Merryfield, M. L. (1985) Curr. Top. Cell Regul. 27, 41–49
3. Patel, M. S., and Roche, T. E. (1990) FASEB J. 4, 3224–3233
4. Perham, R. N. (2000) Annu. Rev. Biochem. 69, 961–1004
5. Fries, M., Stott, K. M., Reynolds, S., and Perham, R. N. (2007) J. Mol. Biol. 366, 132–139
6. Ciszak, E. M., Korotchkina, L. G., Dominika, P. M., Sidhu, S., and Patel, M. S. (2002) J. Biol. Chem. 278, 21240–21246
7. Kato, M., Wynn, R. M., Chuang, J. L., Tso, S.-C., Machius, M., Li, J., and Chuang, D. T. (2008) Structure (Lond.) 16, 1849–1859
8. Seifert, F., Ciszak, E., Korotchkina, L., Golbik, R., Spinka, M., Dominika, P., Sidhu, S., Brauer, J., Patel, M. S., and Tittmann, K. (2007) Biochemistry 46, 6277–6287
9. Brautigam, C. A., Chuang, J. L., Tomchick, D. R., Machius, M., and Chuang, D. T. (2005) J. Mol. Biol. 350, 543–552
10. Yu, X., Hiromasa, Y., Tsen, H., Stoops, J. K., Roche, T. E., and Zhou, Z. H. (2008) Structure (Lond.) 16, 104–114
11. Howard, M. J., Fuller, C., Broadhurst, R. W., Perham, R. N., Tang, J.-G., Quinn, J., Diamond, A. G., and Yeaman, S. J. (1998) Gastroenterology 115, 139–146
12. Kato, M., Chuang, J. L., Tso, S.-C., Wynn, R. M., and Chuang, D. T. (2005) EMBO J. 24, 1763–1774
13. Ruhul Momen, A. Z. M., Hirota, H., Hayashi, F., and Yokoyama, S. (2006) Protein Data Bank 10.2210/pdb2dnxe/pdb
14. Brautigam, C. A., Wynn, R. M., Chuang, J. L., Machius, M., Tomchick, D. R., and Chuang, D. T. (2006) Structure (Lond.) 14, 611–621
15. Ciszak, E. M., Makal, A., Hong, Y. S., Vettaikorumakankauv, A. K., Korotchkina, L. G., and Patel, M. S. (2006) J. Biol. Chem. 281, 648–655
16. Kato, M., Li, J., Chuang, J. L., and Chuang, D. T. (2007) Structure (Lond.) 15, 992–1004
17. Steussy, C. N., Popov, K. M., Bowker-Kinley, M. M., Sloan, R. B., Jr., Harris, R. A., and Hamilton, J. A. (2001) J. Biol. Chem. 276, 37443–37450
18. Wynn, R. M., Kato, M., Chuang, J. L., Tso, S.-C., Li, J., and Chuang, D. T. (2008) J. Biol. Chem. 283, 25305–25315
19. Vassilyev, D. G., and Symerski, J. (2007) J. Mol. Biol. 370, 417–426
20. Sanderson, S. J., Miller, C., and Lindsay, J. G. (1996) Eur. J. Biochem. 236, 103–111
21. Hiromasa, Y., Fujisawa, T., Aso, Y., and Roche, T. E. (2004) J. Biol. Chem. 279, 6921–6933
22. Frank, R. A. W., Pratap, J. V., Pei, X. Y., Perham, R. N., and Luisi, B. F. (2005) Structure (Lond.) 13, 1119–1130
23. Jung, H.-I., Cooper, A., and Perham, R. N. (2003) Eur. J. Biochem. 270, 4488–4496
24. Smolle, M., and Lindsay, J. G. (2006) Biochem. Soc. Trans. 34, 815–818
25. Smolle, M., Prior, A. E., Brown, A. E., Cooper, A., Byron, O., and Lindsay, J. G. (2006) J. Biol. Chem. 281, 19772–19780
26. Harris, R. A., Bowker-Kinley, M. M., Wu, P., Jeng, J., and Popov, K. M. (1997) J. Biol. Chem. 272, 19746–19750
27. Laue, T. M., Shah, B. D., Ridgeway, R. M., and Pelletier, S. L. (1992) in Analytical Ultracentrifugation in Biochemistry and Polymer Science (Harding, S. E., Rowe, A. J., and Horton, J. C., eds) pp. 90–125, The Royal Society of Chemistry, Cambridge, UK
28. Schuck, P. (2000) Biophys. J. 78, 1606–1619
29. Schuck, P., Perugini, M. A., Gonzales, N. R., Howlett, G. J., and Schubert, D. (2002) Biophys. J. 82, 1096–1111
30. Deka, R. K., Brautigam, C. A., Tomson, F. L., Lumpkins, S. B., Tomchick, D. R., Machius, M., and Norgard, M. V. (2007) J. Biol. Chem. 282, 5944–5958
31. Houtman, J. C. D., Yamaguchi, H., Handa, S., Braiman, A., Bowden, B., Appella, E., Schuck, P., and Samelson, L. E. (2006) Nat. Struct. Mol. Biol. 13, 798–805
32. Balbo, A., Minor, K. H., Velikovsky, C. A., Mariuzza, R. A., Peterson, C. B., and Schuck, P. (2005) Proc. Natl. Acad. Sci. U. S. A. 102, 81–86
33. Jilkia, J. M., Rahmatullah, M., Kazemi, M., and Roche, T. E. (1986) J. Biol. Chem. 261, 1858–1867
34. Barrera, C. R., Namihira, G., Hamilton, L., Munk, P., Eley, M. H., Linn, T. C., and Reed, L. J. (1972) Arch. Biochem. Biophys. 148, 343–358
35. Harris, R. A., Hawes, J. W., Popov, K. M., Zhao, Y., Shimomura, Y., Sato, J., Jaskiewicz, J., and Hurley, T. D. (1997) Adv. Enzyme Regul. 37, 271–293
36. de la Torre, J. G., Huertas, M. L., and Carrasco, B. (2000) Biophys. J. 78,

Stoichiometries of a Reconstituted Human PDC

FIGURE 8. Protein-protein interactions in the native human PDC. A, a close-up view of E3BD (ribbons representation) bound to E3 (surface) (14). One monomer of E3 is colored orange, and the other is blue. The approximate position of the dyad axis of the E3 dimer is shown by the black symbol. Most of E3BD is colored green, but those residues with atoms that would clash with a second bound E3BD are shown in purple. B, schematic model of the native human PDC. The dodecahedral 60-meric core is shown, with the black symbol.

C, close-up view of E3BD (14). One monomer of E3 is colored orange, and E2p docked to the active site. E2p and E3BD are purple, and the cyan subunits in E2 are colored blue.
Stoichiometries of a Reconstituted Human PDC

719–730

37. Velazquez-Campoy, A., Leavitt, S., and Freire, E. (2004) in Methods in Molecular Biology (Fu, H., ed) pp. 35–54, Humana Press, Inc., Totowa, NJ
38. Gilbert, G. A., and Jenkins, R. C. L. (1956) Nature 177, 853–854
39. Gilbert, G. A., and Jenkins, R. C. L. (1959) Proc. R. Soc. Lond. Ser. A 253, 420–437
40. Mande, S. S., Sarfaty, S., Allen, M. D., Perham, R. N., and Hol, W. G. J. (1995) Structure (Lond.) 4, 277–286
41. Danson, M. J., Fersht, A. R., and Perham, R. N. (1978) Proc. Natl. Acad. Sci. U. S. A. 75, 5386–5390
42. Hackert, M. L., Oliver, R. M., and Reed, L. J. (1983) Proc. Natl. Acad. Sci. U. S. A. 80, 2226–2230
43. Sigurskjold, B. W. (2000) Anal. Biochem. 277, 260–266
44. Izard, T., Ævarsson, A., Allen, M. D., Westphal, A. H., Perham, R. N., de Kok, A., and Hol, W. G. J. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 1240–1245
45. Frank, R. A. W., Titman, C. M., Pratap, J. V., Luisi, B. F., and Perham, R. N. (2004) Science 306, 872–876